202 related articles for article (PubMed ID: 25376537)
1. In vivo markers of Parkinson's disease and dementia with Lewy bodies: current value of the 5G4 α-synuclein antibody.
Maetzler W; Pilotto A; Apel A; Deuschle C; Kuebart G; Heinzel S; Liepelt-Scarfone I; Schulte C; Reusch D; Schleicher E; Rothfuss O; Schneider A; Dodel R; Gasser T; Berg D
Acta Neuropathol; 2014 Dec; 128(6):893-5. PubMed ID: 25376537
[No Abstract] [Full Text] [Related]
2. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG
Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042
[TBL] [Abstract][Full Text] [Related]
3. Cerebrospinal fluid levels of alpha-synuclein, amyloid β, tau, phosphorylated tau, and neuron-specific enolase in patients with Parkinson's disease, dementia with Lewy bodies or other neurological disorders: Their relationships with cognition and nuclear medicine imaging findings.
Katayama T; Sawada J; Kikuchi-Takeguchi S; Kano K; Takahashi K; Saito T; Okizaki A; Hasebe N
Neurosci Lett; 2020 Jan; 715():134564. PubMed ID: 31733322
[TBL] [Abstract][Full Text] [Related]
4. Cerebrospinal fluid markers analysis in the differential diagnosis of dementia with Lewy bodies and Parkinson's disease dementia.
Gmitterová K; Gawinecka J; Llorens F; Varges D; Valkovič P; Zerr I
Eur Arch Psychiatry Clin Neurosci; 2020 Jun; 270(4):461-470. PubMed ID: 30083957
[TBL] [Abstract][Full Text] [Related]
5. Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias.
Parnetti L; Chiasserini D; Bellomo G; Giannandrea D; De Carlo C; Qureshi MM; Ardah MT; Varghese S; Bonanni L; Borroni B; Tambasco N; Eusebi P; Rossi A; Onofrj M; Padovani A; Calabresi P; El-Agnaf O
Mov Disord; 2011 Jul; 26(8):1428-35. PubMed ID: 21469206
[TBL] [Abstract][Full Text] [Related]
6. Tau/α-synuclein ratio and inflammatory proteins in Parkinson's disease: An exploratory study.
Delgado-Alvarado M; Gago B; Gorostidi A; Jiménez-Urbieta H; Dacosta-Aguayo R; Navalpotro-Gómez I; Ruiz-Martínez J; Bergareche A; Martí-Massó JF; Martínez-Lage P; Izagirre A; Rodríguez-Oroz MC
Mov Disord; 2017 Jul; 32(7):1066-1073. PubMed ID: 28548309
[TBL] [Abstract][Full Text] [Related]
7. The cognitive profile and CSF biomarkers in dementia with Lewy bodies and Parkinson's disease dementia.
Andersson M; Zetterberg H; Minthon L; Blennow K; Londos E
Int J Geriatr Psychiatry; 2011 Jan; 26(1):100-5. PubMed ID: 21157855
[TBL] [Abstract][Full Text] [Related]
8. [Alpha-Synuclein in blood and cerebrospinal fluid of patients with alpha-synucleinopathy].
Ono K; Yamada M
Rinsho Byori; 2014 Mar; 62(3):241-5. PubMed ID: 24800499
[TBL] [Abstract][Full Text] [Related]
9. Using cerebrospinal fluid marker profiles in clinical diagnosis of dementia with Lewy bodies, Parkinson's disease, and Alzheimer's disease.
Kaerst L; Kuhlmann A; Wedekind D; Stoeck K; Lange P; Zerr I
J Alzheimers Dis; 2014; 38(1):63-73. PubMed ID: 23948928
[TBL] [Abstract][Full Text] [Related]
10. Autoantibodies against amyloid and glial-derived antigens are increased in serum and cerebrospinal fluid of Lewy body-associated dementias.
Maetzler W; Berg D; Synofzik M; Brockmann K; Godau J; Melms A; Gasser T; Hörnig S; Langkamp M
J Alzheimers Dis; 2011; 26(1):171-9. PubMed ID: 21593566
[TBL] [Abstract][Full Text] [Related]
11. Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies.
Parnetti L; Tiraboschi P; Lanari A; Peducci M; Padiglioni C; D'Amore C; Pierguidi L; Tambasco N; Rossi A; Calabresi P
Biol Psychiatry; 2008 Nov; 64(10):850-5. PubMed ID: 18395699
[TBL] [Abstract][Full Text] [Related]
12. Increased CSF α-synuclein levels in Alzheimer's disease: correlation with tau levels.
Slaets S; Vanmechelen E; Le Bastard N; Decraemer H; Vandijck M; Martin JJ; De Deyn PP; Engelborghs S
Alzheimers Dement; 2014 Oct; 10(5 Suppl):S290-8. PubMed ID: 24439167
[TBL] [Abstract][Full Text] [Related]
13. Low levels of soluble NG2 in cerebrospinal fluid from patients with dementia with Lewy bodies.
Nielsen HM; Hall S; Surova Y; Nägga K; Nilsson C; Londos E; Minthon L; Hansson O; Wennström M
J Alzheimers Dis; 2014; 40(2):343-50. PubMed ID: 24448788
[TBL] [Abstract][Full Text] [Related]
14. CSF levels of the neuronal injury biomarker visinin-like protein-1 in Alzheimer's disease and dementia with Lewy bodies.
Luo X; Hou L; Shi H; Zhong X; Zhang Y; Zheng D; Tan Y; Hu G; Mu N; Chan J; Chen X; Fang Y; Wu F; He H; Ning Y
J Neurochem; 2013 Dec; 127(5):681-90. PubMed ID: 23800322
[TBL] [Abstract][Full Text] [Related]
15. Measurements of auto-antibodies to α-synuclein in the serum and cerebral spinal fluids of patients with Parkinson's disease.
Akhtar RS; Licata JP; Luk KC; Shaw LM; Trojanowski JQ; Lee VM
J Neurochem; 2018 Jun; 145(6):489-503. PubMed ID: 29500813
[TBL] [Abstract][Full Text] [Related]
16. Serum heart-type fatty acid-binding protein and cerebrospinal fluid tau: marker candidates for dementia with Lewy bodies.
Mollenhauer B; Steinacker P; Bahn E; Bibl M; Brechlin P; Schlossmacher MG; Locascio JJ; Wiltfang J; Kretzschmar HA; Poser S; Trenkwalder C; Otto M
Neurodegener Dis; 2007; 4(5):366-75. PubMed ID: 17622779
[TBL] [Abstract][Full Text] [Related]
17. Cerebrospinal α-synuclein in α-synuclein aggregation disorders: tau/α-synuclein ratio as potential biomarker for dementia with Lewy bodies.
Llorens F; Schmitz M; Varges D; Kruse N; Gotzmann N; Gmitterová K; Mollenhauer B; Zerr I
J Neurol; 2016 Nov; 263(11):2271-2277. PubMed ID: 27544498
[TBL] [Abstract][Full Text] [Related]
18. Tau protein, beta-amyloid₁₋₄₂ and clusterin CSF levels in the differential diagnosis of Parkinsonian syndrome with dementia.
Vranová HP; Hényková E; Kaiserová M; Menšíková K; Vaštík M; Mareš J; Hluštík P; Zapletalová J; Strnad M; Stejskal D; Kaňovský P
J Neurol Sci; 2014 Aug; 343(1-2):120-4. PubMed ID: 24928081
[TBL] [Abstract][Full Text] [Related]
19. CSF α-synuclein, tau, and amyloid β in Parkinson's disease.
Shi M; Zhang J
Lancet Neurol; 2011 Aug; 10(8):681; author's reply 681-3. PubMed ID: 21777821
[No Abstract] [Full Text] [Related]
20. Decreased CSF amyloid beta42 and normal tau levels in dementia with Lewy bodies.
Kanemaru K; Kameda N; Yamanouchi H
Neurology; 2000 May; 54(9):1875-6. PubMed ID: 10802808
[No Abstract] [Full Text] [Related]
[Next] [New Search]
